Global Anti-Rheumatics Market, 2021-2027

July 2021 | 81 pages | ID: G108C9CED7BCEN
Gen Consulting Company

Abstracts

The global anti-rheumatics market is projected to grow at a compound annual growth rate (CAGR) of 3.7% during the forecast period 2021-2027, according to the new report published by Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global anti-rheumatics market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, company share of market leaders, growth rate and market segments.

The anti-rheumatics market is segmented on the basis of drug class, type, and region. The anti-rheumatics market is segmented as below:

By Drug Class:

• corticosteroids
• disease modifying anti-rheumatic drugs
• nonsteroidal anti-inflammatory drugs
• uric acid drugs
• others

By Type:

• over-the-counter drugs
• prescription-based drugs

By Region:

• Asia-Pacific
• Europe
• North America
• Middle East and Africa (MEA)
• South America

The anti-rheumatics industry is characterized by a high level of market share concentration. The market research report covers the analysis of key stake holders of the anti-rheumatics market. Some of the leading players profiled in the report include AbbVie Inc., Amgen Inc., Bristol Myers Squibb (BMS), Eli Lilly And Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, UCB SA, among others.

*list is not exhaustive, request free sample to get a complete list of companies

Historical & Forecast Period

This research report provides analysis for each segment from 2017 to 2027 considering 2020 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global anti-rheumatics market.
• To classify and forecast the global anti-rheumatics market based on drug class, type, and region.
• To identify drivers and challenges for the global anti-rheumatics market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global anti-rheumatics market.
• To conduct pricing analysis for the global anti-rheumatics market.
• To identify and analyze the profile of leading players operating in the global anti-rheumatics market.

Why Choose This Report

• Gain a reliable outlook of the global anti-rheumatics market forecasts from 2021 to 2027 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Market Definition
1.2 Key Benefit
1.3 Market Segment

PART 2. METHODOLOGY

2.1 Primary
2.2 Secondary

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Market Size and Forecast
4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
4.4 Impact of COVID-19 Pandemic

PART 5. GLOBAL MARKET FOR ANTI-RHEUMATICS BY DRUG CLASS

5.1 Corticosteroids
  5.1.1 Market Size and Forecast
5.2 Disease Modifying Anti-Rheumatic Drugs
  5.2.1 Market Size and Forecast
5.3 Nonsteroidal Anti-Inflammatory Drugs
  5.3.1 Market Size and Forecast
5.4 Uric Acid Drugs
  5.4.1 Market Size and Forecast
5.5 Others
  5.5.1 Market Size and Forecast

PART 6. GLOBAL MARKET FOR ANTI-RHEUMATICS BY TYPE

6.1 Over-The-Counter Drugs
  6.1.1 Market Size and Forecast
6.2 Prescription-Based Drugs
  6.2.1 Market Size and Forecast

PART 7. GLOBAL MARKET FOR ANTI-RHEUMATICS BY REGION

7.1 Asia-Pacific
  7.1.1 Market Size and Forecast
7.2 Europe
  7.2.1 Market Size and Forecast
7.3 North America
  7.3.1 Market Size and Forecast
7.4 Middle East And Africa (Mea)
  7.4.1 Market Size and Forecast
7.5 South America
  7.5.1 Market Size and Forecast

PART 8. KEY COMPETITOR PROFILES

8.1 AbbVie Inc.
8.2 Amgen Inc.
8.3 Bristol Myers Squibb (BMS)
8.4 Eli Lilly And Company
8.5 Johnson & Johnson
8.6 Merck & Co., Inc.
8.7 Novartis AG
8.8 Pfizer Inc.
8.9 Roche Holding AG
8.10 UCB SA
*LIST IS NOT EXHAUSTIVE

PART 9. PATENT ANALYSIS

9.1 Patent Statistics
9.2 Regional Analysis
9.3 Trends Analysis
DISCLAIMER
ABOUT GEN CONSULTING COMPANY